APDN Applied DNA Sciences Inc Return on Sales by Gross Profit

Official company branding of Applied DNA (APDN)

Applied DNA Sciences (APDN) gross margin history correlates with the implementation of ESG standards and the minimization of chemical waste, with the current level standing at 29.50. The high scalability of molecular tagging across various industries facilitates expansion. Business stability is supported by the transition to contract PCR production for gene therapy, which reduces reliance on volatile safety tests.

Applied DNA Sciences, Inc. (APDN): Gross Margin from 07/04/2022 to 10/07/2025

Analytical breakdowns and data insights for company Applied DNA Sciences, Inc. (APDN)

Fundamental valuation:APDN, Applied DNA Sciences, Inc.
Signature product of adnas.com

The metric is calculated as the difference between total revenue and direct costs, reflecting the efficiency of cost-of-sales management and pricing power. A high indicator value confirms the business's ability to generate profit at the basic production level. Stable utilization of DNA synthesis laboratories and the optimization of PCR systems directly determine the gross margin trajectory, demonstrating the operational resilience of Applied DNA Sciences (APDN).

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Profitability Stoke Corp (STOK)|Return on Sales by Gross Profit BioLife|Gross Margin WVE (Wave Life Sciences Ltd)|MAZE: Gross Return on Sales|Sionna Therapeutics, Inc. - Gross Margin|Gross Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Return on Gross Profit|QURE - Return on Sales by Gross Profit|MGTX (MeiraGTx Corp) - Gross Margin|Gross Profit Margin REGENXBIO Inc. RGNX|Gross Profitability Solid Biosciences (SLDB)|Ocugen Corp - Gross Return on Sales|Gross Profitability Pacific Biosciences PACB|Gross Profit Ratio BNTC (Benitec)|Design Corp - Gross Margin|Rocket Pharmaceuticals - Gross Profit Ratio|Gross Return on Sales 4D Molecular Therapeutics, Inc.|Gross Profit Margin Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Gross Margin|Gross Profit Margin Editas EDIT|Gross Margin SLN|ProQR Therapeutics - Gross Return on Sales|Gross Margin CDXS (Codexis, Inc.)|SGMO: Gross Return on Sales|Nautilus Biotechnology - Gross Margin|Gross Profit Rate MGX (Metagenomi, Inc)|DTIL: Gross Margin|GBIO: Gross Profit Ratio|Gross Profitability Boundless Bio Inc.|Return on Gross Profit Exicure (XCUR)|Gross Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Gross Profit Rate|Mustang Bio, Inc. - Return on Gross Profit|RNAZ - Return on Gross Profit|BNGO: Return on Gross Profit|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability